Table I.
Characteristics of patients with chronic hepatitis B sequentially treated with lamivudine and adefovir
| Characteristic | Lamivudine group (N=15) | Adefovir group (N=15) | P value |
|---|---|---|---|
| Age(yr) | 25.53 ± 9.23 | 29.53 ± 6.67 | NS |
| Median (range) | 38 (18-70) | 40 (20-72) | 0.9 |
| Mean ± SD | 29.73 ± 10.06 | 25.33 ± 6.64 | 0.7 |
| Sex (male/female) | 12/3 | 9/6 | 0.2 |
| Serum alanine aminotransferase(IU/l) | |||
| Baseline Median (range Mean ± SD | 85 (80-109) 93 ± 8.5 | 84 (74-100) 88.6 | 0.0001 |
| End of treatment Median (range Mean ± SD | 26 (20-37) 27.2 ± 5.26 | 28 (13-44 28.13 ± 8.66 | |
| Positive for HBeAg (%) | 87 | 87 | - |
| Serum bilirubin (mg/dl) | |||
| Mean ± SD | 0.73 ± 0.33 | 0.77 ± 0.25 | 0.89 |
| Median (range) | 0.7 (0.2-1.3) | 0.6 (0.4-1.2) | - |
| Histologic activity index score | |||
| Baseline Median (range Mean ± SD | 3 (2-6 2.8 ± 1.01 | 4 (2-9) 3.53 ± 1.92 | 0.53 |
| End of treatment Median (range Mean ± SD | 1 (1-2) 1.27 ± 0.45 | 2 (1-3 1.53 ± 0.74 | 0.6 |
| Fibrosis score | |||
| Baseline Median (range Mean ± SD | 3 (2-6) 2.8 ± 1.01 | 5 (2-9 3.53 ± 1.92 | 0.53 |
| End of treatment Median (range Mean ± SD | 1 (0-1 0.47 ± 0.5 | 1 (0-3) 0.47 ± 0.8 | - |
| Serum HBVDNA (copies/ml) Median (range) | |||
| Baseline Post-follow up | 8.3 × 1010 - 8.7 × 105(5.6 × 109 ± 2.1 × 1010 9.8 × 106- 890 (1.4 × 106 ± 2.6 ×106) | 6.7 × 1010-3.3 × 105(4.8 × 109 ± 1.7 × 1010) 8.1 × 107- 258 (8.9 × 106 ± 2.1 × 107) | 0.001 |
| Hepatic HBV DNA(copies/ml) Median (range) | |||
| Baseline Post-follow up | 9 × 107 - 789 (7.6 × 106 ± 1.3 × 107 9.1 × 104- 831 (2.2 × 104 ± 3.5 ×104) | 4.1 × 107-6.2 × 103 (7.6 × 106 ± 1.3 × 107 9.3 × 106- 91 (1.1 × 106 ± 2.7 × 106) | 0.001 |